Characterization of biological features and chemosensitivity of a new experimental lung metastasis model originating from the MXT mouse mammary adenocarcinoma

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1171-1180

  Farinelle, Sophie ^a   Dedecker, Robert ^a   Malonne, Hughes ^a   Werry, Jean ^a   Darro, Francis ^b   Kiss, Robert ^a,c,d  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Laboratoire L Lafon   (France)

^c FNRS   (Belgium)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Chemosensitivity; Experimental model; Lung metastasis; Mouse; MXT mammary adenocarcinoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CELL CLONE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL;

ADENOCARCINOMA; ANIMALS; CHROMATIN; FEMALE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PLOIDIES;

EID: 0032991024     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Watson CS, Medina D and Clarck JH: Estrogen receptor characterization in a transplantable mouse mammary tumor. Cancer, Res 37: 3344-3348, 1977.
2. Kiss R, Paridaens R, Leclercq G and Danguy A: Sensitivity of the hormone dependent MXT mouse mammary tumor to estradiol during tumoral growth. An autoradiographic study. Eur J Cancer Clin Oncol 22: 849-856, 1986.
3. Paridaens R, Danguy A, Leclercq G, Kiss R and Heuson JC: Effect of castration and estradiol pulse on cell proliferation in the uterus and the MXT mouse mammary tumor. J Natl Cancer Inst 74: 1239-1246, 1985.
4. Kiss R, Paridaens R, Heuson JC and Danguy A: Effect of progesterone on cell proliferation in the MXT mouse hormone sensitive mammary neoplasm. J Natl Cancer Inst 77: 173-178, 1986.
5. Kiss R, Danguy A, Heuson JC and Paridaens R: Syhergism or antagonism between estradiol and progesterone on the cell kinetic parameters of the MXT mouse mammary tumor. J Natl Cancer Inst 78: 573-579, 1986.
6. de Launoit Y and Kiss R: In vivo influence of androgens on the cell kinetics and chromatin pattern of the MXT mouse mammary tumor treated or not by aminogluthetimide. J Cancer Res Clin Oncol 115: 129-138, 1989.
7. Kiss R, de Launoit Y, L'Hermite-Baleriaux M, L'Hermite M, Paridaens R, Danguy A and Pasteels JL: Effect of prolactin and estradiol administrations on cell proliferation in the uterus and the MXT mouse mammary neoplasm. J Natl Cancer Inst 78: 993-998, 1987.
8. Kiss R, de Launoit Y, Danguy A, Paridaens R and Pasteels JL: Influence of pituitary grafts or prolactin administrations on the hormone sensitivity of "ovarian-independent" mouse mammary MXT tumors. Cancer 49: 2945-2951, 1989.
9. de Launoit Y, Kiss R, Danguy A and Paridaens R: Effect of ovariectomy, hypophysectomy and/or GnRH analog (HRF) administration on the cell proliferation of the MXT mouse hormone-dependent mammary tumor. Eur J Cancer Clin Oncol 23: 1443-1450, 1987.
10. Milovanovic SR, Monje E, Szepeshazi K, Radulovic S and Schally A: Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing hormone-releasing hormone in MXT mouse mammary carcinoma. J Cancer Res Clin Oncol 119: 273-278, 1993.
11. Milovanovic SR, Radulovic S and Schally A: Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumour. Breast Cancer Res Treat 24: 147-158, 1993.
12. Szepeshazi K, Lilovanovic S, Lapis K, Groot K and Schally AV: Growth inhibition of estrogen-independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21: 181-192, 1992.
13. Spruss T, Bernhardt G, Schonenberger H and Engel J: Antitumour activity of miltefoxine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models. J Cancer Res Clin Oncol 119: 142-149, 1993.
14. Spruss T, Schertl S, Schneider MR, Gust R, Bauer K and Schonenberger H: (Meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine)-dichloroplatinum (II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer. J Cancer Res Clin Oncol 119: 707-716, 1993.
15. Maucher A and von Angerer E: Antiproliferative activity of casodex (ICI 176,334) in hormone-dependent tumours. J Cancer Res Clin Oncol 119: 669-674, 1993.
16. von Angerer E and Erber S: 3-alkyl-2-phenylbenzo(b)thiophenes: nonsteroidal estrogen antagonists with mammary tumour inhibitory activity. J Steroid Biochem Mol Biol 41: 557-562, 1992.
17. Michna H, Gehring S, Kuhnel W, Nishino Y and Schneider MR: The antitumor potency of progesterone antagonists is due to their differentiation potential. J Steroid Biochem Mol Biol 43: 203-210, 1992.
18. Nishino Y, Schneider MR, and Michna H: Enhancement of the antitumour efficacy of the antiprogestin, onapristone, by combination with the antiestrogen ICI 164,384. J Cancer Res Clin Oncol 120: 298-302, 1994.
19. Kiss R, Lenglet G and Danguy A: Binding of fluorescein isothiocyanate conjugated lectins to MXT mouse mammary neoplasm and their relation to steroid receptor status. Anticancer Res 6; 209-214, 1986.
20. Budel V, Pauwels O, Francisco J, Gasperin P, Pasteels JL and Kiss R: Characterization of chemotherapy-induced morphonuclear modifications in the P388 leukemia and the MXT mammary tumour model ofthe mouse. J Cancer Res Clin Oncol 121: 89-97, 1995.
21. Pauwels O and Kiss R: Monitoring of chemotherapy-induced morphonuclear modifications by means of digital cell image analysis. J Cancer Res Clin Oncol 119: 533-540, 1993.
22. Danguy A, Kiss R, Leclercq G, Heuson JC and Pasteels JL: Morphology of MXT mouse mammary tumors. Correlation with growth characteristics and hormone sensitivity. Eur J Cancer Clin Oncol 22: 69-76, 1986.
23. Bradner WT and Claridge CA: Screening systems. In: Antineoplastic agents. Remcres WA (ed.) Wiley-Interscience, pp 41-82, 1984.
24. Pihl A: UICC Study Group on chemosensitivity testing of human tumors. Problems - Applications - Future prospects. Int J Cancer 37: 1-5, 1986.
25. Salmon I, Coibion M, Larsimont D, Badr-El-Din H, Verhest A, Pasteels JL and Kiss R: Fine needle aspirations of breast cancers compared to imprint smears by means of digital cell image analysis. Anal Quant Cytol Histol 13: 193-200, 1991.
26. Kiss R, Salmon I, Camby I, Gras S and Pasteels JL: Characterization of factors in routine laboratory protocols which significantly influence the Feulgen reaction. J Histochem Cytochem 41: 935-945, 1993.
27. Kiss R, Leclercq G, Danguy A: Histological staining by tritiated actinomycin D: a useful tool to study neoplastic cell heterogeneity and estrogen sensitivity of mammary tumors. Oncology 42: 129-132, 1985.
28. Lespagnard L, Kiss R, Devleeschouwer N, Paridaens R, Danguy A and Atassi G: Influences of inoculation sites and tumoral cell culture techniques on the phenotype of a mixed cartilage-and bone-producing mouse mammary tulihor. Anticancer Res 6: 1329-1336, 1986.
29. Kiss R, Devleeschouwer N, Paridaens R, Danguy A Heuson JC, Atassi G: Phenotypic change of the transplantable MXT mammary adenocarcinoma into mixed bone producing sarcoma-like tumors. Anticancer Res 6: 753-760, 1986.
30. Abbona GC, Papotti M, Gugliotta P, Pecchio F and Rapellino M: Immunohistochemical detection of carcinoembryonic antigen (CEA) in non-neoplastic lung disease. Int J Biol Markers 8: 240-243, 1993.
31. Kim J, Kaye FJ, Henslee JG, Shively JE, Park JG, Lai SL, Linnoila RI, Mulshine JL and Gazdar AF: Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer 52: 718-725, 1992.
32. Grimm T, Riethmueller G, Johnson JP: Characteristics of carcinoembryonic antigen (CEA) expressed in different cell types: Evidence that CEA can function as an adhesion molecule and as a repulsion molecule. Biochem Biophys Res Commun 204: 1225-1234, 1994.
33. Jothy S, Yuan SY and Shirota K: Transcription of carcinoembryonic antigen in normal colon and colon carcinoma. In situ hybridization study and implication for a new in vivo functional model. Am J Pathol 143: 250-257, 1993.
34. Zhou H, Stanners CP and Fuks A: Specificity of anti-carcinoembiyonic antigen monoclonal antibodies and their effects on CEA-mediated adhesion. Cancer Res 53: 3817-3822, 1993.
35. Jessup JM, Petrick AT, Toth CA, Ford R, Meterissian S, O'Hara CJ, Steel G Jr and Thomas P: Carcinoembryonic antigen: Enhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer 67: 464-470, 1993.
36. Kobayashi H, Shinohara H, Takeuchi K, Itoh M, Fujie M and Saitoh M, Terao T: Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effect on tumor cell invasion and metastasis. Cancer Res 54: 844-849, 1994.
37. Dumont JA, Jones WD Jr and Bitonti AJ: Inhibition of the experimental metastasis and cell adhesion of B6D2F1 melanoma cells by inhibitors of protein kinase C. Cancer Res 52: 1195-1200, 1992.
38. Esumi N, Fan D and Fidler IJ: Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 51: 4549-4556, 1991.
39. Sakaguchi Y, Emi Y, Maehara Y, Kohnoe S and Sugimachi K: Combined treatment of adriamycin and dipyridamole inhibits lung metastatis of B16 melanoma cells in mice. Eur Surg Res 22: 213-218, 1990.
40. Pulverer G, Buss G, Ko HL and Beuth J: Propionibacterium acnesmetabolites inhibit experimental lung metastasis of murine sarcoma L-1 in BALB/C mice. Int J Med Microbiol Viorol Parasitol Infect Dis 277: 364-370, 1992.
41. Iwamoto Y, Fujita J, Sugioka Y and Yig SR: A synthetic laminin peptide inhibits the enhancement by cyclophosphamide of experimental lung metastatis of human fibrosarcoma cells. Clin Exp Metast 10: 183-189, 1992.
42. Sharkey RM, Weadock KS, Natale A, Haywood L, Aninipot R, Blumenthal RD and Goldenberg DM: Successful radioimmunotherapy for lung metastasis of human colonie cancer in nude mice. J Natl Cancer Inst 83: 627-632, 1991.
43. Damen JE, Greenberg AH and Wright JA: Transformation and amplification of the K-fgf proto-oncogene in NIH-3T3 cells, and induction of metastatic potential. Biochim Biophys Acta 1097: 103-110, 1991.
44. Kaba DS, Pierceall WE, Price JE and Ananthaswamy HN: Immune response to progressor variants derived from transfection of an ultraviolet radiation-induced C3H mouse regressor tumor cell line with activated Harvey-ras oncogene. Cancer Res 50: 3159-3166, 1990.
45. Weinstein JN, Kohn KW, Grever MR, Viswanadham VN, Rubinstein LV, Monks AP, Scuderio DA, Welch L, Koutsoukos AD, Chiausa AJ and Paull KD: Neural computing in cancer development: predicting mechanism of action. Science 258: 447-451, 1992.